Hayashi Yoshitaka
Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University, Chikusa-Ku, Nagoya, 464-8601 Japan.
Department of Endocrinology, Nagoya University Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Diabetol Int. 2024 Feb 26;15(3):348-352. doi: 10.1007/s13340-024-00696-8. eCollection 2024 Jul.
The regulation of plasma amino acid levels by glucagon in humans first attracted the attention of researchers in the 1980s. Recent basic research using animal models of glucagon deficiency suggested that a major physiological role of glucagon is the regulation of amino acid metabolism rather than to increase blood glucose levels. In this regard, novel feedback regulatory mechanisms that are mediated by glucagon and amino acids have recently been described between islet alpha cells and the liver. Increasingly, hyperglucagonemia in humans with diabetes and/or nonalcoholic fatty liver diseases is reported to likely be a compensatory response to hepatic glucagon resistance. Severe glucagon resistance due to a glucagon receptor mutation in humans causes hyperaminoacidemia and islet alpha cell expansion combined with pancreatic hypertrophy. Notably, a recent report showed that the restoration of glucagon resistance by liver transplantation resolved not only hyperglucagonemia, but also pancreatic hypertrophy and other metabolic disorders. The mechanisms that regulate islet cell proliferation by amino acids largely remain unelucidated. Clarification of such mechanisms will increase our understanding of the pathophysiology of diseases related to glucagon.
20世纪80年代,胰高血糖素对人体血浆氨基酸水平的调节首次引起了研究人员的关注。最近使用胰高血糖素缺乏动物模型的基础研究表明,胰高血糖素的主要生理作用是调节氨基酸代谢,而不是提高血糖水平。在这方面,最近已经描述了胰岛α细胞和肝脏之间由胰高血糖素和氨基酸介导的新型反馈调节机制。越来越多的报道称,糖尿病和/或非酒精性脂肪性肝病患者的高胰高血糖素血症可能是对肝脏胰高血糖素抵抗的一种代偿反应。人类因胰高血糖素受体突变导致的严重胰高血糖素抵抗会引起高氨基酸血症和胰岛α细胞扩张,并伴有胰腺肥大。值得注意的是,最近的一份报告显示,肝移植恢复胰高血糖素抵抗不仅解决了高胰高血糖素血症,还解决了胰腺肥大和其他代谢紊乱问题。氨基酸调节胰岛细胞增殖的机制在很大程度上仍未阐明。阐明这些机制将增进我们对与胰高血糖素相关疾病病理生理学的理解。